RCT: Adjustable intragastric balloon resulted in significant weight loss at 32 weeks, but intolerance caused early removal of the device in 17% of patients, and device-related serious adverse events were observed in 4% of patients.

Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

In this trial, when an adjustable intragastric balloon was combined with lifestyle modification in adults with obesity, significant weight loss was achieved and maintained for 6 months following device removal. https://t.co/jg7z5ldeC7 #GITwitter pic.twitter.com/Pi9PVAeWzo

— The Lancet (@TheLancet) November 16, 2021